Shots:
- PeptiDream to receive an upfront along with R&D funding and may eligible for ~$2.2B in development, regulatory, and commercial milestones upon specified achievement along with royalties on sales on any Alnylam products
- The agreement will utilize PeptiDream’s peptide discovery platform with Alnylam’s siRNA-conjugate-based delivery to identify peptide ligands
- The collaboration will helps to yield multiple treatment opportunities at targeting disease-causing mRNA transcripts in a broad variety of tissue types
Click here to read full press release/ article | Ref: Businesswire | Image: Alnylam
The post Alnylam Signs a License Agreement with PeptiDream to Develop and Commercialize Peptide-siRNA Conjugates for Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues first appeared on PharmaShots.
